Signal Genetics
Miragen Therapeutics, Signal Genetics Complete Merger, New Financing Round
Privately held Miragen will pick up Signal's Nasdaq listing, and the combined company is scheduled to begin trading today.
Signal Genetics Regains Compliance With Nasdaq Listing Requirement
As of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.
Miragen Therapeutics, Signal Genetics Agree to Merge
The combined company will be focused on Miragen's microRNA therapeutics programs, following the divestiture of Signal's molecular diagnostic assets.
Signal Genetics Revenues Up 27 Percent on Record Test Volume
Revenue from tests billed for clinical patients rose 93 percent year over year, the firm said, though its net loss widened to $2.8 million.
Signal Genetics Reports Q4 Revenues Essentially Flat
The company said sales of its MyPRS test for myeloma risk increased during the quarter, but full-year 2015 revenues fell because of increased R&D costs.
May 14, 2015
Signal Genetics Q1 Revenues Slide 41 Percent
Apr 30, 2015
Signal Genetics Lab Nabs CAP Accreditation
Mar 27, 2015
Signal Genetics Reports Flat 2014 Revenues
Feb 23, 2015
Signal Genetics Closes $9M Public Offering of Stock
Feb 17, 2015
Signal Genetics Prices $9M Public Offering of Stock
Nov 17, 2014
Signal Genetics Q3 Revenues Move up 32 Percent
Aug 13, 2014
Jun 17, 2014
Signal Genetics Increases IPO Target to up to $12.1M
Mar 19, 2014